Neko Health's US Entry Faces Different Regulatory Gauntlet Than European Markets

Neko Health opens its first US clinic in New York this year after securing $700 million in Series C funding at a $7 billion valuation. The AI-powered body-scanning startup has scaled in the UK and Sweden without insurance reimbursement, but US expansion introduces FDA device classification, state-level licensing, and absent insurance coverage for elective preventive scans. These constraints reshape unit economics and regulatory pathway in ways the company has not publicly detailed.